TENALI M 500 10.S

About

TENALI M 500 is a combination medication used for the treatment of type 2 diabetes mellitus, containing Teneligliptin and Metformin hydrochloride. Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing the levels of incretin hormones, which in turn enhance glucose-dependent insulin secretion and suppress glucagon secretion. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, leading to decreased glucose absorption from the gastrointestinal tract. This dual mechanism of action provides comprehensive glycemic control by addressing multiple pathophysiological defects in type 2 diabetes, helping patients achieve target blood sugar levels when diet and exercise alone are insufficient.

Uses

• Management of type 2 diabetes mellitus.
• As an adjunct to diet and exercise.
• When monotherapy with Metformin is insufficient.
• In combination with other antidiabetic agents.

Directions For Use

Take orally, usually once or twice daily with meals, as prescribed by your healthcare provider.

Benefits

• Provides dual action for effective blood sugar control.
• Improves both fasting and post-meal glucose levels.
• Helps achieve significant reduction in HbA1c.
• Generally weight-neutral or associated with modest weight loss.
• Low risk of hypoglycemia when used alone.
• Convenient fixed-dose combination therapy.

Side Effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Headache
• Dizziness
• Nasopharyngitis
• Hypoglycemia (especially with other agents)
• Lactic acidosis (rare)
• Metallic taste
• Rash
• Fatigue

Safety Measures

• Alcohol - Avoid excessive alcohol consumption due to the increased risk of lactic acidosis, a rare but serious side effect associated with Metformin.
• Pregnancy - Consult your doctor before use. This medication is generally not recommended during pregnancy unless the potential benefits outweigh the risks to the fetus.
• Breastfeeding - Not recommended during breastfeeding as Metformin is excreted in breast milk and the effects of Teneligliptin on infants are unknown.
• Liver - Contraindicated in severe hepatic impairment due to the Metformin component, which increases the risk of lactic acidosis.
• Kidney - Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²). Dose adjustment is required for moderate impairment.
• Lung - Use with caution in severe respiratory conditions that may lead to hypoxia, as this can increase the risk of lactic acidosis with Metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.